In chronic myeloid leukaemia (CML) led by the BCR-ABL fusion, β-catenin has a well-documented role in mediating resistance to tyrosine kinase inhibitors53. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.